STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3749 by analyst upside · 2026-06-27
LIVN
LivaNova PLC
Healthcare · Market Cap $5B · P/E 42.6x
ANALYST PRICE TARGET
-2.3%
implied upside to consensus target
Current Price $83.43
Consensus Target $81.5
Bull Target $95.0
Bear Target $67.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
5
Hold
3
Sell
0
52-Week Low $41.02
52-Week High $83.95
YTD Return +37.6%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) 42.6x
Forward P/E 18.0x
EPS (TTM) $1.96
PEG Ratio 0.91
Dividend Yield N/A
Revenue (TTM) $1.4B
Profit Margin 7.5%
52-WEEK RANGE
52-Week Low $41.02
52-Week High $83.95
Current Price $83.43
Bear Target $67.0
Bull Target $95.0
● Now $83.43 ● Target $81.5
TRADING DATA
Avg Volume 795K
YTD Return +37.6%
Analyst Count 10
Consensus Buy
Upside to Target -2.3%
Last Updated 2026-06-27

ANALYST SUMMARY

LivaNova PLC (LIVN) is currently trading at $83.43 with a Wall Street consensus price target of $81.5, which is 2.3% below the current price over the next 12 months. 10 analysts currently cover LIVN, with a consensus rating of Buy - 70% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $95.0, while the most cautious has a target of $67.0.

LIVN operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 37.6% year-to-date and is currently trading near the upper end of its 52-week range of $41.02 – $83.95.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LIVN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-05-07 Building track record
Mizuho — Reiterated
Outperform → Outperform 2026-05-07 Building track record
Baird — Reiterated
Outperform → Outperform 2026-05-07 Building track record
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-02-27 Building track record
Needham — Reiterated
Buy → Buy 2026-02-25 20% win rate (5 calls)
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-01-09 Building track record
Stifel — Reiterated
Buy → Buy 2026-01-07 Building track record
Keybanc ● Initiated
Overweight 2025-12-19 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
55
out of 100
Coverage depth
18/30
Consensus clarity
23/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →